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Summary Studies over the past few decades have showed a clear association
between cigarette smoking and the development of chronic airway obstruction. Yet,
only a minority of smokers is affected so that in many, even heavy, smokers,
pulmonary function remains within normal limits. While carcinogens have been well
characterized, there is only limited information about the constituents of cigarette
smoke responsible for inducing chronic airway obstruction. In addition, the associated
risks factors for airway obstruction in smokers have not been totally identified. The
present paper is a review of the recently accumulated facts concerning the intimate
action of cigarette smoke at the level of large and small airways and lung
parenchyma. The role of classical inflammatory cells such as neutrophils and alveolar
macrophages is reviewed, but emphasis is put on recent evidence indicating the
involvement of CD8þ T-lymphocytes and possibly eosinophils in the genesis of the
structural changes leading to airways obstruction. The mechanisms by which airway
inflammation and remodelling cause airway narrowing and airflow limitation are
discussed, along with the associated loss of lung elasticity secondary to destructive
emphysema. Other biological, epidemiological, physiopathological, and clinical
aspects are analyzed, stressing such fundamental aspects as the defence mechanisms,
the morpho-functional correlations, the identification of susceptible smokers, and
the early detection of airway obstruction, both in specialized laboratories and in
primary care.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Evidence accumulated in the past 30 years shows an
irrefutable association between the long-term
inhalation of cigarette smoke and the development
of obstructive airway disease.1–4 Cigarette smoke is
the most important factor associated with the
occurrence of chronic airway obstruction, being
responsible for 80–90% of cases of chronic airway
obstruction in the USA.5 Deaths from chronic airway
obstruction are several times more numerous and
the loss of pulmonary function with age is more
accelerated in smokers than non-smokers.6 In
general, a dose–response relationship exists be-
tween the amount of tobacco smoked and the level
of obstruction2,3 and a progressive reduction in
mean flow rates and an increase in the incidence
of severe obstruction with increasing pack-year
ARTICLE IN PRESS
KEYWORDS
Cigarette smoking;
Chronic airway obstruction;
FEV1;
Airway inflammation;
Airway remodelling;
CD8þ T-lymphocytes;
Eosinophils
*Corresponding author. INSERM Unit !e 420, Epid!emiologie Sant !e
Travail, Facult !e de M !edecine, 9 av de la For #et de Haye, B.P 184,
Vandoeuvre-l "es-Nancy 54505, France.
E-mail address: abraham.bohadana@nancy.inserm.fr
(A. Bohadana).
0954-6111/$ - see front matter & 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2003.09.005
Respiratory Medicine (2004) 98, 139–151
exposure have been documented.4 However, in a
significant number of heavy smokers, pulmonary
function remains within normal limits, a finding
indicating that other factors, either of genetic and/
or environmental nature, are also involved in the
production of airway obstruction.
Risk factors for the development of
chronic airway obstruction
Several risk factors are likely to explain the
susceptibility of smokers to develop airway ob-
struction and a thorough discussion on this topic is
available elsewhere.7 Briefly, concerning cigarette
smoke itself, the risk of airway obstruction does not
seem to be influenced neither by the nicotine or tar
content8 nor the addition of a filter.9 However,
studies in adults have shown an increased pre-
valence of symptoms following passive smoke
exposure at the workplace and at home10 while
studies in children have demonstrated an increase
in respiratory illnesses and a decrease in levels
of pulmonary function especially when mothers
smoke.11
There is evidence that the rate of decline in
forced expiratory volume in one second (FEV1) in
smokers is correlated with the subject’s response to
non-specific bronchial challenge. Studies in the
general population have shown bronchial hyperre-
sponsiveness (BHR) to be an important predictor of
lung function12,13 while studies in large populations
of subjects with early obstruction showed BHR
to be a strong predictor of changes in FEV1
(% predicted), after controlling for baseline lung
function, age, sex, baseline smoking history and
changes in smoking status.14
Another important factor likely to play a role in
the development of chronic airway obstruction in
response to smoking is genetic predisposition, the
best illustration of which is the propensity to the
development of early onset, familial emphysema in
patients with a1-antitrypsin deficiency.15 However,
this enzyme deficiency is present in only 1–2% of
obstructive patients and, although the homozygous
deficiency state (Pi-Z phenotype) is clearly asso-
ciated with the occurrence of emphysema, its
presence may not suffice to produce airway
obstruction. Indeed, in an earlier study we found
that among six males with severe deficiency
(homozygous Pi-Z phenotype) only fourFall of
whom were ex-smokers seeking help because of
respiratory complaintsFhad severe functional im-
pairment.16 The remaining two, who were first
screened at a centre for preventive medicine, had
little or no symptoms and remarkably well pre-
served mechanical function despite active smoking
and similar a1-antitrypsin blood levels. As a whole,
this highly deficient group was clinically and
functionally indistinguishable from a non-deficient
group of similar age and tobacco consumption.
Other risk factors which have been associated
with the development of chronic airway obstruc-
tion include age, air pollution, childhood illnesses,
occupation, social class, and alcohol use.17 How-
ever, the extent to which these factors act
individually or in combination to increase the risk
of airway obstruction is not completely known.
More studies are necessary to clarify this important
issue.
Cigarette smoke-associated syndromes
Smoking-induced lung diseases are complex and
can be defined clinically (chronic bronchitis),
pathologically (emphysema) and functionally
(chronic airway obstruction).18 This triple descrip-
tion reflects differences in the way the various
authors recognize and describe the cigarette
smoke-related diseases. Therefore, it is important
to realize that chronic airway obstruction is not one
disease but a term encompassing at least three
phenotypes namely obstructive chronic bronchitis,
emphysema, and small airway disease. The diag-
nosis of obstructive chronic bronchitis is based on
the objective documentation of airway obstruction
and symptoms of cough and sputum production.18
Incidentally, smokers who consider themselves
‘‘healthy’’ may develop mild symptoms which are
related to physiological changes and inflammatory
markers reflecting events in the central rather than
the peripheral airways.19 Emphysema is defined in
anatomical terms as a permanent destructive
enlargement of the airspaces distal to the terminal
bronchioles.18 Finally, small airway disease is
defined as a functional abnormality not revealed
by standard spirographic tests such as the FEV1,
20
evidenced by the use of so called ‘‘sensitive tests’’,
and by peculiar anatomic alterations.
Understanding airflow limitation
To understand how tobacco smoke induces the
development of airway obstruction it is useful to
revise the mechanisms of airflow limitation. The
tracheobronchial tree is a highly branched system
of conducting tubes which can be divided schema-
tically into large airways (airways with cartilage in
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their walls, usually greater than 2mm in internal
diameter) and small airways or bronchioles (air-
ways without cartilage in their walls, usually less
than 2mm in internal diameter). Distal to the
bronchioles is the terminal bronchiole, and beyond
it the acinus. The branching of the tracheobron-
chial tree would be symmetric if each parent
branch divided into two daughter branches of equal
diameter and length. In fact, the system is slightly
asymmetric, with the diameter of two daughter
branches being greater than the diameter of the
parent branch and the number of airways increas-
ing more than the diameter of the individual
airways decreases.21 In such a system, the major
site of airway resistance does not lie in the smallest
airways as might be expected from rational con-
siderations but in the medium sized bronchi, with
most of the pressure drop occurring in the airways
up to the seventh generation.22 The reason is the
enormous increase in the cumulated cross-sectional
area of the airways, from the trachea to the lung
periphery, which explains the noticeable diminu-
tion of flow resistance in the peripheral airways.
Although initial measurements suggested that less
than 20% of airway resistance could be attributed
to airways less than 2mm i.d.,23,24 later experi-
ments showed that 30–40% is probably a more
realistic figure.25
In a system like the tracheobronchial tree,
airflow can be limited either by reducing the
pressure applied to the system or by narrowing
the tubes (bronchi), or both. The pressure applied
to airflow is the recoil pressure of the lung, which is
determined by its elastic properties. Airway nar-
rowing is usually characterized by parameters of
forced expiration, and the mechanisms of flow
limitation during this manoeuvre can be explained
on the basis of the simple model proposed by Mead
and colleagues.26 At end-inspiration, immediately
before forced expiration, flow is zero and intrab-
ronchial pressure, i.e. the pressure within the
airways from the mouth to the alveoli, is atmo-
spheric. At the same time, the pressure surrounding
the airways (intrapleural) is negative and equal to
the static recoil pressure of the lung. This interplay
makes the pressure difference between the airway
lumen and the intrapleural pressure to be positive
thus tending to expand the airways (Fig. 1a). Early
in forced expiration, both intrapleural and alveolar
pressures rise greatly. As air flows, intrabronchial
pressure drops to a point where it equals intra-
pleural pressure. Downstream from this ‘‘equal
pressure point’’ (EPP) airway collapse occurs and
flow is determined only by the difference between
alveolar pressure and intrapleural pressure. Beyond
the EPP the airway resistance is irrelevant. At high
lung volume (e.g. end maximal inspiration), the
EPP is located in central airways, probably in the
vicinity of lobar bronchi, where the cumulated
cross-sectional area is small. As lung volume
decreases, the EPP moves toward the periphery so
that at low lung volumes flow is dependent of the
resistance of the airways between the alveoli and
the EPP, i.e. the small airways (Fig. 1b). In
cigarette smokers, peripheral airway resistance
can be increased by changes in the airways
themselves (e.g. inflammation, swelling of the
mucosa, contraction of smooth muscle, retention
of secretions, etc.) or in the static (e.g. destruction
of alveolar attachments, decrease in lung recoil)
and dynamic (e.g. dynamic compression) forces
acting upon them (Fig. 1c). Other factors favouring
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Figure 1 Model of lung to illustrate airflow limitation in
healthy subjects and smokers with small airway disease
(see text for discussion). (a) End-inspiration, normal. (b)
Forced expiration, normal: EPP in lobar bronchi; dynamic
compression. (c) Small airway disease: EPP moves toward
periphery; dynamic compression.
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this ‘‘dynamic narrowing’’ include the magnitude of
the flow and the compressibility of the airways.
Factors involved in cigarette smoke-
induced airway obstruction
Although cigarette smoking is the major cause of
chronic airway obstruction only 24–47% of the
smokers actually develop clinically significant air-
way obstruction.6 Among the environmental factors
likely to influence an individual’s response to
cigarette smoke, the smoke composition and mode
of delivery play an important role.
Smoke components involved in the
pathogenesis of cigarette smoke-induced
obstruction
Cigarette smoke is a complex, heterogeneous
mixture of about 4000 substances. By convention,
the smoke fraction that passes through a glass fibre
filter is referred to as the gas phase and the
retained fraction as particulate phase.5 Main gas
phase components include carbon dioxide (CO2),
carbon monoxide (CO), irritants, and carcinogens.
Particulate phase is a mixture of nicotine and tar, a
generic term used to define the particles of smoke
and the condensable components of the gas phase,
minus nicotine and water. Tar contains various
aromatic hydrocarbons, including carcinogens (e.g.
non-volatile nitrosamines, aromatic amines, ben-
zopyrene) and radioactive elements (e.g Polonium-
210). The composition of the smoke directly
inhaled through the cigarette into the lung (main-
stream smoke) is different from that formed
between puffs (sidestream smoke) and that ex-
haled (exhaled smoke), both constituting the
smoke breathed by passive smokers. Unlike carci-
nogens, which have been well characterized, there
is only limited information about the constituents
of cigarette smoke responsible for inducing chronic
obstructive lung disease.
Several studies failed to demonstrate a clear,
direct association between the tar yield and the
development of airway obstruction. Higgenbottom
and colleagues27 related the tar yield and the
number of cigarettes smoked daily with lung
function and respiratory symptoms in more than
18,000 male civil-servants. They found that tar
yield influenced phlegm production but not the
degree of airflow obstruction, and suggested that
the irritant agents leading to obstruction were
probably contained in the gaseous phase of tobacco
smoke. Paoletti and colleagues28 examined 582
smokers and 621 ex-smokers and found that the
estimated tar exposure from current cigarette
consumption was significantly associated with
cough and phlegm, and lung function measure-
ments. Petitti and Friedman29 examined the asso-
ciation between smoking cigarettes with low yield
of tar and nicotine and respiratory diseases by
reviewing the medical records of 4610 current
smokers and 2035 never smokers. They found that
smoking lower tar cigarettes was not associated
with a lower risk for chronic obstructive pulmonary
disease. Brown and colleagues30 observed that for
women but not for men, the rates of chronic cough
and chronic phlegm were higher with higher tar
yield of cigarettes smoked. However, pulmonary
function tests were not done so the relationship
between tar yield and the degree of airway
obstruction could not be examined. Finally, Krzy-
zanowski and colleagues8 analyzed data collected
in the Tucson Epidemiologic Study of Airway
Obstructive Disease and found that the tar, nicotine,
and CO contents were important only in connection
with the number of cigarettes smoked and had no
independent effect on pulmonary function.
There is no evidence of a direct relationship
between the nicotine yield and the development of
airway obstruction.8,31 However, nicotine was
found to be chemotactic for human neutrophils,32
the first cell to be recruited in smoke-induced lung
inflammation, and could therefore play an impor-
tant role in the onset of the lung response
eventually leading to airway obstruction (see below).
Several irritant substances (e.g. acrolein, cresol,
acetone, phenol, etc.) present in the two phases of
smoke can act either directly on the airways,
damaging the mucocilliary apparatus of the bron-
chial mucosa and favouring the development and
progression of bronchitis, or indirectly, favouring
lung destruction. This is the case of the potent
irritant acrolein, which appears to favour the
release by alveolar macrophages of leukotriene
B4, a chemotactic substance responsible for the
recruitment neutrophils in the lung parenchyma,
the presumed first event leading to emphysema.33
Finally, the role of free radicals, which are
present in both smoke phases, as agents favouring
the development of emphysema and airway ob-
struction seems now well established.33 In gas
phase, free radicals react with oxygen to form
oxy-radicals in smoke, and inactivate alpha-1-
protease inhibitor (a1PI) in a 2-step process: a fast
reaction, which is completed in minutes, and a
slower process which continues for hours or days.
Free radicals in the particulate (tar) phase are
stable indefinitely, and are capable of reduc-
ing molecular oxygen to produce superoxide,
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eventually leading to hydrogen peroxide and
hydroxyl radicals.
Smoking parameters in the development of
airway obstruction
The manner of smoking is one of the major factors
controlling lung’s exposure to cigarette smoke. In
general, smokers take a puff into the mouth and
after a variable pause mix the smoke with air and
inhale. The reason why this two-phase pattern is
adopted is not clearly understood but it could be a
means to reduce the acute airway response to
smoke inhalation. Deposition of particles of smoke
depends on their size, the pattern of breathing,
and the pulmonary structure–function relation-
ships. The median size of particulate matter in
smoke ranges from 0.3 to 0.5 mm but it may
increase in actual smoking, with growth in size
occurring by coalescence or by hygroscopic growth
after absorption of moisture in the respiratory
tract. Larger particles tend to deposit in airway
branch points by impaction, while smaller particles
tend to deposit by sedimentation in areas of
slowest flow, at the lung periphery.
Individual smokers show a wide variation in the
volumes inhaled while smoking a single cigarette
whatever the tar yield. Using respiratory inductive
plethysmography, Tobin and colleagues34 assessed
the pattern of inhalation in 19 habitual smokers.
They found that the mean volumes inhaled varied
from 0.27 to 1.97 l (mean7SD¼ 0.7970.45) and the
mean duration of smoke inhalation varied from 2 to
6.8 s (mean7SD¼ 4.571.3). In addition, they found
that the smokers’ perception of their inhaled
volume was quite imprecise and pointed out that
such imprecision could be responsible for the
purported lack of relationship between smoke
inhalation and loss of lung function.35 Another
study from the same group showed that in a single
session of 150min, switching from a high- to low-
tar cigarette caused a significant increase in the
puff volume from 39710 to 52715ml, respectively
(Po0:001).36 It was argued that if the gas phase is
the important component for the development of
airway obstruction, subjects taking larger puff
volumes may be at an increased risk of obstruction.
The inhalation pattern seems to be important in
the pathogenesis of airway obstruction, and smo-
kers with obstruction have patterns that differ from
those of smokers without obstruction.37 In addition,
higher ventilation/perfusion ratios in the lung
apices could lead to excess deposition of smoke in
these areas thus explaining the preferential loca-
lization of centriacinar emphysema.38 Longitudinal
studies comparing objective indices of smoke
inhalation and pulmonary function are necessary
to assess the importance of inhaling patterns in
determining loss of lung function.
Pulmonary response to the inhalation of
cigarette smoke
In healthy individuals, a complex system called
‘‘host defence mechanisms’’ limits the penetration
of substances through the mucosal surface and
removes particles deposited along the airways and
in the alveoli. These mechanisms include anatomic
barriers in the airways, clearance activity provided
by coughing and the mucociliary apparatus, and
several substances of non-immunologic and immu-
nologic nature. The upper regions of the bronchial
tree are lined with ciliated cells, the ‘‘mucociliary
escalator’’, in charge of removing inhaled particles
from the lungs. Chronic cigarette smoking may
induce an increased number of abnormal cilia
which could constitute a determinant of the
mucociliary clearance impairment.39 Airways be-
yond generation 14 do not have this protection,
being therefore vulnerable to the effects of inhaled
particles, especially those in the respirable range
(0.5–5 mm) such as particulate matter of smoke
(median size¼ 0.5 mm). Despite the efficiency of
host defences, during cigarette smoking 5–10% of
the tar/nicotine particles are deposited in the
tracheobronchial region and 30–40% in the alveolar
region. Obviously, the amount of deposited sub-
stances and the site of deposition may vary
according to the physical properties of the smoke
particles and the smoking pattern (volume and
depth of inhalation, etc.). For the average smoker,
particle deposition is greatest at airway bifurca-
tions, the most common site of bronchogenic
carcinoma. The chronic, continuing action of
cigarette smoke on lung structures induce an array
of lung responses that will eventually lead to
airway obstruction in the susceptible smoker. The
initial event after the first few cigarette puffs is an
alteration of the airway epithelial cell barrier
leading to airway inflammation. Several studies
have shown that this inflammatory process is quite
widespread and extends to the central airways,40,41
peripheral airways24,42–44 and lung parenchyma as
well.45,46
Airway inflammation
It has long been recognized that exposure
to cigarette smoke is associated with airway
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inflammation.40 The combination of direct effects
of cigarette smoke and indirect damage caused by
effects of inflammatory cells leads to a series of
epithelial changes including squamous metaplasia,
hyperplasia of mucous glands, changes in mucocili-
ary clearance, and fibrotic changes. Several types
of inflammatory cells are thought to play a role in
this process.
An increase of neutrophils in the airway lumen
has been documented by bronchoalveolar (BAL)
fluid and sputum analysis in smokers with mild to
moderate chronic airway obstruction47–50 and a
good correlation was observed between the num-
ber of neutrophils and the annual decline in FEV1.
47
However, biopsies studies in mild to moderate
airway obstruction showed a dissociation between
the increased number of neutrophils in the airway
lumen and a lack of increase in these cells numbers
in the subepithelium.41 To explain this discrepancy,
Saetta and her colleagues postulated that neutro-
phils could migrate across the tissue into the lumen
thus making their accumulation undetectable by
tissue analysis but detectable by analysis of BAL
fluid or induced sputum.51 Incidentally, studies of
surgical specimens and biopsies by the same team
showed an increased number of neutrophils in both
epithelium and bronchial gland of patients with
established chronic airway obstruction thus provid-
ing evidence for neutrophilia not only in the airway
lumen but also in specific areas in the airway wall
of these subjects.52
Another cell involved in the process of smoke-
induced airway inflammation is the T-lymphocyte.
Studies of bronchial biopsies taken through a
bronchoscope or from surgical specimens have
shown these cells to infiltrate the epithelium and
submucosa of patients with mild to moderate
airway obstruction, along with macrophages and
eosinophils.41,52–57 Using immunohistochemical
methods various studies showed that in contrast
with asthmaFwhose inflammation is dominated by
the CD4þ subsetFin chronic airway obstruction
the T-lymphocyte inflammation is largely due to the
CD8þ subset thus making the balance of the
CD4þ /CD8þ cell ratio to tilt in favour of CD8þ
cells. Concerning lung distribution, the CD8þ
infiltrate was found to be ubiquitous, being present
in all lung compartments including the central
airways52,57–59 the peripheral airways59–61 and the
lung parenchyma.62
The role of T-lymphocytes in smoke-induced
airway inflammation has been explored by several
authors. In a study examining the effect of smoking
on small airway submucosal immunopathology,
Lams and colleagues61 found an increase in total
and activated eosinophils, neutrophils, and CD8þ /
CD3þ cell ratio in smokers along with a decrease in
CD4(þ )/CD8(þ ) cell ratio. Interestingly, the in-
creased CD8þ /CD3þ cell ratio showed a dose
relationship to pack-years smoked and an inverse
relationship to months since smoking cessation
suggesting an association between cigarette smok-
ing and CD8þ cells. In bronchial biopsies of
bronchitic smokers with and without chronic airway
obstruction O’Shaugnessy and colleagues57 found
that as airflow obstruction develops, neutrophils
and CD8þ lymphocytes increase in number and
proportion in association with the decline of lung
function. These authors suggested that individuals
with genetically determined higher CD8þ cell
population may be more susceptible to a further
increase in CD8þ cells recruitment induced by
smoking and that this might explain why only a
proportion of smokers proceed to develop chronic
airway obstruction. Saetta and her colleagues60
examined whether the inflammatory process in the
small airways differs in surgical specimens of
smokers with (n ¼ 9) and without (n ¼ 7) chronic
airflow obstruction. They found that the number of
CD8þ T-lymphocytes and the smooth muscle area
were increased in smokers with obstruction, while
the number of neutrophils, macrophages, and
CD4þ lymphocytes were similar in the two groups.
When all the smokers were considered jointly, both
the number of CD8þ T-lymphocytes and the value
of smooth muscle area showed a significant
negative correlation with FEV1. Taken together,
these studies support the idea that the CD8þ cells
might play a role in the development of smoke-
induced airway obstruction.
In contrast with T-lymphocytes, the role of
eosinophils in the pathogenesis of chronic airway
obstruction in smokers is more controversial. While
airway eosinophilia has been documented in smo-
kers with chronic obstruction during exacerba-
tions,55 an increase in eosinophils in clinically
stable patients has been documented by some
investigators48,54,61,63,64 but not by others.65 On the
other hand, eosinophilia has been documented in
BAL lavage fluid in a subset of asthma-like patients
with chronic airway obstruction who respond to
steroid and have increased responsiveness.66
The role of eosinophils in the development of
chronic airway obstruction in smokers is still
controversial. Lams and colleagues61 used immu-
nohistochemistry to examine peripheral lung sec-
tions obtained at surgery from smokers (n ¼ 22),
ex-smokers (n ¼ 17) and non-smokers (n ¼ 5). The
number of eosinophils and activated eosinophils in
the small-airway submucosa of smokers was in-
creased compared with non-smokers. In addition, a
good correlation was found between the number of
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eosinophils and neutrophil numbers. However, no
difference was found between groups with and
without airway obstruction in the number of
eosinophils infiltrating the submucosa, a finding
suggesting that eosinophilia may be related to
smoking per se. Balzano and colleagues50 evaluated
airway inflammation by cellular analysis and mea-
surement of eosinophil cationic protein (ECP) levels
in induced sputum and correlated the inflammation
markers with functional indices of obstruction. A
group of 46 subjects with clinically stable chronic
obstructive pulmonary disease (n ¼ 10), patients
with mild asthma (n ¼ 15), asymptomatic smokers
(n ¼ 11), and healthy control subjects (n ¼ 10) was
examined. As expected, eosinophils were found to
be significantly higher in patients with asthma than
in the other groups, while neutrophils were
significantly higher in patients with chronic ob-
structive pulmonary disease than in the other
groups. However, eosinophils and ECP levels were
increased in patients with chronic airway obstruc-
tion as compared with healthy controls. In addition,
sputum eosinophils and sputum ECP levels were
inversely correlated with indices of obstruction
both in patients with established chronic airway
obstruction and asymptomatic smokers. Finally,
significant correlations were found between spu-
tum eosinophils and neutrophils as well as sputum
neutrophils and sputum ECP, leading the authors to
conclude that eosinophilic and neutrophilic inflam-
mation may be closely correlated and that eosino-
phils may play a role in the pathogenesis of chronic
airway inflammation in chronic airway obstruction.
To summarize, there is evidence that neutro-
phils, CD8þ cells, and possibly eosinophils play a
role in cigarette smoke-induced chronic airway
obstruction. While neutrophils predominate on
mucosal surface of large airways, CD8þ cells are
distributed extensively along all lung compart-
ments. This is especially true of mild and moderate
obstruction; as more severe airflow limitation
develops the number of neutrophils increases
suggesting that these cells may play a role in the
progression of the disease. Finally, an increase
in the number of eosinophilsFwhich correlated
with the neutrophil numbersFhas been documen-
ted in the sputum and small airway submucosa of
patients with stable chronic airway obstruction and
smokers, respectively.
Inflammation in the lung parenchyma
As discussed above, smoking is known to be
associated with the presence of neutrophils in the
distal airspaces.67 The exact mechanisms governing
neutrophil recruitment and sequestration are not
completely understood but it seems that the
process is influenced by a loss of capacity of
neutrophils to deform, an important mechanism
allowing these cells to squeeze through pulmonary
capillaries, along with other factors.68 This de-
creased deformability would delay the passage of
neutrophils through the alveolar capillary bed
thereby enhancing the release of elastase and
reactive oxygen intermediates. These substances
would then be capable to cause tissue destruction
through the association of a protease–antiprotease
imbalance and an oxidant–antioxidant imbalance.
According to this theory, under normal circum-
stances proteolytic enzymes (e.g. elastase, cathe-
psin G) and matrix metalloproteases of neutrophil
origin are neutralized by the antiprotease protec-
tive mechanisms (e.g. a1 AT); however, in smokers,
this antiprotease activity is impaired by the
oxidation of a1 antitrypsin by cigarette smoke. As
a consequence, the unopposed proteolytic activity
damages the lung parenchyma by degrading elas-
tin, enhancing neutrophil recruitment, and increas-
ing collagen deposition. Of course, neutrophils are
not the only source of elastolytic enzymes and
other cells, especially the alveolar macrophage,
source of macrophage elastase, likely play a role. In
fact, neutrophils and alveolar macrophages could
interact but their relative contribution to the
process of lung inflammation and emphysematous
destruction is not completely understood.
Studies showed that the cellularity of the
alveolar walls is increased in smokers. Eidelman
and co-workers69 examined the lungs of smokers
(n ¼ 22) undergoing thoracotomy for localized
pulmonary lesions, along with lungs of eight non-
smokers and five smokers who died suddenly of non-
respiratory causes. The number of inflammatory
cells correlated significantly with an index of
alveolar destruction while the number of polymor-
phonuclear cells in smokers was 5 times as great as
in non-smokers; however, the inflammatory cells
were not clearly distinguished from one another. To
attempt to clarify this issue, Saetta and collea-
gues60 examined surgical specimens from non-
smokers (n ¼ 8), asymptomatic smokers with nor-
mal lung function (n ¼ 6), and smokers with chronic
airway obstruction (n ¼ 10). Compared with non-
smokers, smokers with airway obstruction were
found to have an increased number of CD8þ cells
both in the lung parenchyma and the pulmonary
arteries. In addition, the number of CD8þ cells in
both sites was significantly correlated with the
degree of airflow obstruction. These results show
that the lung parenchyma (and the pulmonary
arteries) is (are) involved by an inflammatory
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process whose characteristics are similar to those
previously documented in the central and periph-
eral airways. Finally, Saetta and her colleagues70
reported that the level of small airway inflamma-
tion in smokers correlates with the destruction of
the alveolar wall attached to the airways (alveolar
attachments). They suggested that by-products of
inflammatory cells could weaken the alveolar tissue
and facilitate its rupture at the point where
attachments join with the outer airway wall and
where mechanical stress is maximal. As a result,
two types of emphysema were described.71 The
first, centrilobular emphysema, is characterized by
focal destruction restricted to respiratory bronch-
ioles and the central portions of the acinus; it is
commonly found in smokers and is usually more
severe in the upper lung regions. The second,
panacinar emphysema, involves the destruction of
alveolar walls in a uniform manner and is found in
smokers who develop emphysema early in life and
in subjects with a deficiency of a1 antitrypsin.
Summary of cigarette smoke-induced
inflammation
How do inflammatory cells work to promote airway
damage? Although each cell can work on its own it
is likely that they work in concert. The following
sequence of events has been proposed as an
attempt to combine their inflammatory action.72
In the beginning, the inflammatory reaction would
involve the neutrophil followed by the alveolar
macrophage in the epithelial surfaces of the lung.
These cells would damage epithelial cells and the
interstitial protein structures, which would be
processed into peptides and recognized by T cells,
initiating their activation and proliferation. Once
activated, T cells could recruit other neutrophils
and alveolar macrophages, as well as eosinophils,
to the site of inflammation. Indeed, CD8þ cells are
capable of switching to IL-5 production, a well
described eosinophil chemoattractor and activation
cytokine, and producing IL-8, a powerful chemoat-
tractor for neutrophils. By this mechanism, CD8þ
cells may play a central role in coordinating the
influx of eosinophils and neutrophils in smoke-
induced small airway inflammation.
Airway remodelling and lung destruction:
the morphologic basis of airflow limitation
It has been known for 35 years that the increase in
airways resistance in patients with chronic airway
obstruction is due to disease in the peripheral
airways.24 Airway remodelling is the term coined to
define the structural changes that occur in the
airway wall due to acute inflammatory events and/
or chronic inflammation and repair. Several studies
have shown that airway remodelling and inflamma-
tion in the small airways are associated with
chronic airway obstruction.73–75 These processes
combine with proteolytic lung destruction to
decrease maximal expiratory flow from the lung.
When a bronchiole is cut in cross-sections three
compartments can be distinguished: (1) the inner
wall, that is the tissue between the luminal surface
and the innermost layer of smooth muscle cells; (2)
the smooth muscle, formed by discontinuous
bundles arranged in a helicoidal fashion around
the airway; and (3) the adventitia, a layer of loose
connective tissue placed between the airway
smooth muscle and parenchyma. In chronic airway
obstruction, the airway remodelling affects these
three layers. In the acute phase of chronic airway
obstruction, there is an increase in deposition of
submucosal and adventitial tissue due to oedema
and proteoglycan deposition, two potentially re-
versible phenomena. With chronic inflammation,
there is progressive collagen deposition and fibrosis
of the airway wall together with smooth muscle
remodelling due both to hypertrophy and hyper-
plasia. Mucosal thickening can amplify the effect of
muscle shortening, adventitial thickening can lead
to greater muscle shortening, and muscle thicken-
ing will lead to greater muscle shortening against
elastic loads. As a result, in airway remodelling, a
given degree of smooth muscle contraction will
cause airway narrowing several fold greater than it
would be observed in a non-remodelled airway.76
Smoke-induced airway obstruction:
morpho-functional correlations
There is evidence that the inflammatory changes in
the small airways make an important contribution
to the functional changes seen in smoke-induced
chronic airway obstruction. Niewoehner and col-
leagues42 were the first to identify the pathological
abnormalities in the small airways of young cigar-
ette smokers. They compared the lungs of young
smokers and non-smokers dying of sudden, non-
hospital deaths and found that the former had a
respiratory bronchiolitis associated with clusters
of pigmented alveolar macrophages and an in-
crease in mural inflammatory cells and denude
epithelium in the membranous bronchioles; they
postulated that these abnormalities were precur-
sors of centriacinar emphysema. Cosio and collea-
gues74 confirmed and extended these observations
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by performing pulmonary function tests in 36
patients, of whom two were non-smokers, 1–3 days
before open-lung biopsy for localized pulmonary
lesions. Using an original pathologic score, they
observed a progressive inflammatory reaction in
the small airways leading to fibrosis with connec-
tive tissue deposition in the airway walls, the most
severe cases showing a substantial degree of
emphysema. They also observed that pulmonary
function deteriorated progressively as the abnorm-
ality in the small airways increased, and that tests
of small airway function were able to separate
subjects with minimal pathologic changes from
those with the most normal airways. These initial
observations were largely confirmed by other
investigators in experiments with lungs obtained
either at surgery or autopsy.77–79 In conjunction,
these studies demonstrate that cigarette smoke
can elicit an early inflammatory reaction in the
membranous and respiratory bronchioles that can
be detected by tests of small airway function in
subjects with normal FEV1.
The progressive nature of cigarette smoke-
induced lesions has been further demonstrated.
Hale and her colleagues80 examined pathologic
changes in the small airways and lung parenchyma
of lungs obtained from persons with a history of
long-term cigarette use and an established clinical
and physiologic diagnosis of chronic airflow ob-
struction, and compared the findings with those of
older, never smokers and persons who had smoked
but did not have severe disease. They found an
orderly progression of the pathologic lesions in the
three groups along with an increase in the number
of airways o400 mm in diameter. In the group with
established chronic airway obstruction, the pre-
mortem FEV1 correlated not only with the average
airway diameter and the proportion of airways
smaller than 400 mm, but also with emphysema. No
small airway variable had any independent pre-
dictive value beyond the severity of emphysema
alone in estimating the level of ventilatory func-
tion. However, as they pointed out, the relative
importance of emphysema as a cause of severe
airflow obstruction had to be tempered because
correlations of individual spirometric function and
pathology were possible only for the group of
smokers with established COPD.
There is evidence that the pattern of airway
obstruction differs according to the type of
destructive emphysema.81–84 Panacinar emphyse-
ma is associated with a loss of elastic recoil and
higher lung compliance whereas centriacinar
emphysema is associated with a higher degree
of airway inflammation and hyperresponsiveness.
In pathological studies, lungs with centriacinar
emphysema were found to have higher total
pathological scores of the small airways and more
airways smaller than 400 mm than lungs with
panlobular emphysema.82 As a consequence, in
centrilobular emphysema, flow decreases as air-
ways abnormalities increase, while elastic recoil
loss would play an additive role. By contrast, in
panlobular emphysema the flow limitation seems to
be mainly a function of reduced elastic recoil.
Saetta and her colleagues84 showed that these two
types of emphysema may be present in pure form or
may overlap each other in which case, as they
emphasized, one type is always clearly predomi-
nant. In these studies, pathological score for airway
abnormalities were highest in pure centriacinar
emphysema and decreased in stepwise fashion as
the amount of panlobular emphysema increased. By
contrast, lung compliance was highest in panlobu-
lar emphysema and decreased as the amount of
centrilobular emphysema increased. Based upon
these observations Saetta and her colleagues84
suggested that panlobular emphysema might result
from a bloodborne mechanism while centriacinar
emphysema, which is characterized by an uneven
pattern of lung destruction associated with more
severe abnormalities in small airways, would be
related to airborne factors. Finally, more recent
studies have shown that high-resolution computer
tomography (HRCT) may reveal early emphysema-
tous lesions in a substantial fraction of smokers
before clinical symptoms have developed.85
An overview of the mechanisms likely to produce
airway obstruction in the susceptible smoker is
shown schematically in Fig. 2.
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Figure 2 Schematic representation of the mechanism of
cigarette smoke-induced chronic airway obstruction.
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Cigarette smoke and airway obstruction:
who is susceptible?
The risk for a smoker of progression toward chronic
airway obstruction is linked to the rapid decline of
FEV1 with age. However, since FEV1 is insensitive to
early changes in the small airways, where the
disease originates, other tests that correlate with
lesions of the small airways should be available. In
one study, Nemery and colleagues86 indirectly
estimated the prognostic significance of tests of
small airway disease, namely the slope of phase III
of the N2 single-breath washout and the bolus
closing volume and closing capacity. They examined
a group of steelworkers, 54 of whom were lifelong
non-smokers and 105 current smokers, ranging
between the ages of 45 and 55. Smokers were
divided into 3 groups: the first group comprised the
subjects with an FEV1/FVC ratio below the normal
limit value (66.6%) while the remaining subjects
were divided into 2 groups according to the
presence or not of an abnormal index of small
airway function. The essential finding was that
among smokers without evidence of airway ob-
struction the subjects with small airway disease
had a significantly lower mean FEV1 than smokers
without small airway disease. The authors specu-
lated that subjects with small airway disease and
low normal FEV1 might be at high risk of chronic
airflow limitation.
The observations of Nemery and colleagues were
further extended by Stanescu and colleagues.87 In a
13 years follow up study of 56 subjects from the
original series above, they showed that those
subjects with impairment of tests of small airway
obstruction but normal FEV1/FVC ratio at the
beginning of the study were at no obvious risk of
rapid functional deterioration. However, in smokers
with a decreased FEV1/FVC, an associated high
phase III slope quite accurately predicted a low
FEV1 at the end of the study. In their view, these
smokers are probably the high-risk smokers who
will reach clinical stages of COPD.
Early detection of obstruction in
primary care
The decrease in lung function in patients with
chronic obstructive lung disease is gradual and
often diagnosed late in its course. In normal non-
smoking subjects, FEV1 declines on average ap-
proximately 30ml per year.6 In susceptible smo-
kers, the age-related decline in FEV1 is accelerated
and rates of decline from 60ml/year88 to 150ml/
year6 have been reported. In a smoker having
smoked for 30 years, such decline would cause the
FEV1 to decrease by 1.8–4.5 l, an amputation likely
to cause disability or even death. Although smoking
cessation does not usually allow FEV1 recovery, it is
the only effective treatment likely to reverse the
steep decline in lung function at all stages of the
disease.88 By consequence, early detection of
smokers at risk of development of obstruction is
of utmost importance as a first step towards
prevention. Indeed, smoking cessation can slow
the rate of decline of FEV1 both in subjects with
mild airway obstruction88 and with normal func-
tion.89 In a study aimed at testing the efficiency of
two regimens of nicotine replacement therapy for
smoking cessation, we observed an average in-
crease of 40ml in the FEV1 of completely abstinent
subjects 1 year after smoking cessation.89
The matter of how feasible is early detection in
primary care has been addressed recently. In a
random group of subjects visiting two semirural
practices in the south east of the Netherlands, van
Schayck and colleagues90 found that 30 smokers,
out of 169 (18%) capable to produce an acceptable
spirometry, were at risk of chronic airway obstruc-
tion (defined as an FEV1o80% predicted). Spiro-
metry was carried out by a trained assistant in four
minutes and the direct costs of detecting one
smoker with airway obstruction was 5–10h. These
and other results91 give support to the idea that
smokers 440–45 years of age who have a smoking
history X10 pack years should be given a spiro-
metric test especially if they are symptomatic.
Conclusion
In conclusion, a clear relationship has been
documented between the chronic inhalation of
cigarette smoke and the development of obstruc-
tive airway disease. A progressive reduction in
mean flow rates and an increase in the incidence of
severe obstruction have been found with increasing
pack-year exposure. However, only a small fraction
of smokers will develop significant airway obstruc-
tion, a finding suggesting that other genetic and/or
environmental factors are also operative in the
production of airway obstruction. Smoke compo-
nents likely to cause airway obstruction are not
completely known but nicotine, irritants such as
acrolein and free radicals might play a role. The
manner of smoking is another factor influencing the
lung’s exposure to cigarette smoke; a considerable
inter- and intra-subject variability has been docu-
mented in the inhaled volume and puff volume.
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After the first few cigarette puffs, an inflammatory
response develops involving several cell types,
especially neutrophils, alveolar macrophages,
CD8þ T-lymphocytes, and possibly eosinophils. In
susceptible subjects, a bronchiolitis develops which
will progress with continuing smoking. After a
variable time, airway inflammation is followed by
airway remodelling, a term defining the structural
changes that occur in the airway wall due to acute
inflammatory events and/or chronic inflammation
and repair. At the same time, the antiprotease
activity of the lung may be compromised by the
oxidation, by cigarette smoke, of antiprotease
protective mechanisms (e.g. a1 AT). Without
opposition, the proteolytic activity may damage
the lung parenchyma leading to destructive em-
physema. This proteolytic lung destruction com-
bines with airway inflammation and remodelling to
produce decrease lung recoil and increased periph-
eral airway resistance, the two main factors
responsible for decreasing maximal expiratory flow
from the lung in cigarette smoke-induced chronic
airway obstruction. Cigarette smoke-induced
chronic airway obstruction is an insidious condition
usually diagnosed at advanced stages. Since smok-
ing cessation is the only treatment likely to reverse
the decline in lung function an early diagnosis is a
challenge of pulmonologists but also of general
practitioners. The condition should be diagnosed as
early as possible and subjects strongly advised to
stop smoking.
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